The most common treatment option for AML is chemotherapy to kill the cancerous cells. Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy. If licenced, guadecitabine would offer a new treatment option for patients that cannot tolerate the standard of care chemotherapy treatments.
Axitinib is a tablet taken twice per day which works by interfering with the growth of the blood vessels which supply blood to the cancer cells. In other types of cancer, Axitinib has been seen to slow down the growth and stop cancers from spreading to other parts of the body. Axitinib is already available to treat RCC which has already advanced or spread, however if axitinib is licenced for use after surgery to prevent the growth and spread of further tumours (as an adjuvant therapy), this may prevent the progression and spread of RCC to other sites of the body.